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Abstract Background: Vandetanib, an inhibitor of vascular endothelial growth factor
receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR), and re-
arranged during transfection (RET), is a developmental oncology drug, that
is in part metabolized by cytochrome P450 (CYP) 3A4. Clinical studies were
performed to assess the potential for 3A4 inhibitors and inducers to affect
exposure to vandetanib.
Objective: The aim of this study was to investigate the effects of a potent
CYP3A4 inducer, rifampicin (Study A), and a potent CYP3A4 inhibitor,
itraconazole (Study B), on the pharmacokinetics of a single 300mg dose of
vandetanib in healthy subjects.
Study Design and Setting: Two phase I, randomized, open-label, two-way
crossover, single-center studies.
Participants and Intervention: Study A: 18 healthy male subjects aged
21–44 years were randomized to receive each of the following two regimens,
separated by a ‡6-week washout period: (i) oral rifampicin 600mg/day on
days 1–31 with a single oral dose of vandetanib 300mg on day 10; and (ii) a
single oral dose of vandetanib 300mg on day 1. Study B: 16 healthy male
subjects aged 20–44 years were randomized to receive each of the following
two regimens, separated by a 3-month washout period: (i) oral itraconazole
200mg/day on days 1–24 with a single oral dose of vandetanib 300mg on day
4; and (ii) a single oral dose of vandetanib 300mg on day 1.
Main Outcome Measure: Blood samples for measurement of vandetanib
(both studies) concentrations and its metabolites, N-desmethylvandetanib
and vandetanib N-oxide (Study A only), were collected before and at various
timepoints after vandetanib administration for up to 28 days (Study A) and
37 days (Study B). Pharmacokinetic parameters were determined using non-
compartmental methods. The area under the plasma concentration-time
curve from time 0 to 504 hours (AUC504) and maximum plasma concen-
tration (Cmax) of vandetanib were compared in the presence and absence of
rifampicin, and in the presence and absence of itraconazole.
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Results: Study A: coadministration of vandetanib with rifampicin resulted
in a statistically significant reduction in AUC504 (geometric least square
[GLS]mean ratio [vandetanib+ rifampicin/vandetanib alone] 0.60; 90% CI
0.58, 0.63). There was no significant difference in Cmax of vandetanib
(GLSmean ratio 1.03; 90% CI 0.95, 1.11). AUC504 and Cmax of N-desme-
thylvandetanib increased by 266.0% and 414.3%, respectively, in the presence
of rifampicin compared with vandetanib alone. Exposure to vandetanib
N-oxide was very low compared with that of vandetanib, but was increased in
the presence of rifampicin. Study B: coadministration of vandetanib with
itraconazole resulted in a significant increase in AUC504 (GLSmean ratio
[vandetanib+ itraconazole/vandetanib alone] 1.09; 90% CI 1.01, 1.18) and no
significant change in Cmax (GLSmean ratio 0.96; 90% CI 0.83, 1.11). Van-
detanib was well tolerated in both studies.
Conclusions:Exposure to vandetanib, as assessed byAUC504 in healthy subjects,
was reduced by around 40% when a single dose was given in combination with
the potent CYP3A4 inducer rifampicin. Because of this, it may be appropriate to
avoid coadministration of potent CYP3A4 inducers with vandetanib. Vandeta-
nib exposure was increased by about 9% when it was taken in combination with
the CYP3A4 inhibitor itraconazole. It is unlikely that coadministration of van-
detanib and potent CYP3A4 inhibitors will need to be contraindicated.
Background
Vandetanib (ZD6474) is a novel, orally avail-
able inhibitor of vascular endothelial growth
factor receptor 2 (VEGFR-2), epidermal growth
factor receptor (EGFR), and rearranged during
transfection (RET) tyrosine kinase activity.[1-3]
VEGFR-2, EGFR, and RET are involved in sig-
naling pathways promoting angiogenesis and tumor
growth.[4-6] Vandetanib is in development as an
anti-tumor drug in several tumor types, including
medullary thyroid cancer.[7] Data have recently been
reported from three double-blind, randomized,
phase III studies of vandetanib in patients with
advanced, previously-treated non-small cell lung
cancer (NSCLC).[8-10] In the ZODIAC (Zactima
in cOmbination with Docetaxel In non-small cell
lungCancer) study, vandetanib in combinationwith
docetaxel produced a significant improvement in
progression-free survival compared with doce-
taxel alone (p < 0.001).[9] Results from the ZEAL
(ZactimaEfficacywithAlimta in Lung cancer)[8]
and ZEST (Zactima Efficacy when Studied ver-
sus Tarceva)[10] studies demonstrated activity
in NSCLC for the combination of vandetanib
with pemetrexed,[8] and for monotherapy with
vandetanib.[10]
In vitro studies have shown that cytochrome
P450 (CYP) 3A4 is the main CYP enzyme involved
in the metabolism of vandetanib.[11] Vandetanib is
converted by CYP3A4 to N-desmethylvandetanib
and by flavine-containing mono-oxygenases in
the kidney (FMO1) and liver (FMO3) to vande-
tanib N-oxide. A recent study in healthy male
subjects using radiolabelled vandetanib con-
firmed the presence of N-desmethylvandetanib
and vandetanib N-oxide in plasma, urine, and
feces.[12] Both N-desmethylvandetanib and van-
detanib N-oxide have shown in vitro pharma-
cologic activity in cellular assays for vascular
endothelial growth factor and epidermal growth
factor.[13] N-desmethylvandetanib is of similar
potency to vandetanib, while vandetanib N-oxide
is >50-fold less active than vandetanib. Since
vandetanib is metabolized by CYP3A4, it was
considered important to determine whether induc-
tion or inhibition of this enzyme would influence
exposure to vandetanib. Oncology patients are
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likely to take a range of other drugs in addition to
their therapy for cancer, possibly including agents
that induce or inhibit metabolic enzymes. Signif-
icant pharmacokinetic drug-drug interactions could
lead to alterations in plasma concentrations of
vandetanib, potentially resulting in a reduction in
efficacy or an increase in drug-related toxicity.
This article reports the results of two studies
investigating potential pharmacokinetic drug-
drug interactions between vandetanib and ri-
fampicin, a potent CYP3A4 inducer (Study A;
AstraZeneca study code D4200C00026), and
vandetanib and itraconazole, a potent CYP3A4
inhibitor (Study B; D4200C00015). Further ob-
jectives included determining the effects of rifam-
picin on the pharmacokinetics of the vandetanib
metabolitesN-desmethylvandetanib and vandetanib
N-oxide (Study A only), and confirming the safety
and tolerability of vandetanib (both studies).
Methods
Study Subjects
Both studies recruited healthy male subjects
aged 21–50 years (Study A) or 21–45 years (Study
B) with no clinically significant medical history or
clinically important abnormalities in vital signs,
ECG, or clinical chemistry, hematology, or uri-
nalysis results, and who had not received any re-
cent treatment with CYP inhibitors or inducers.
The studies were performed in compliance
with the ethical principles of the Declaration of
Helsinki, which are consistent with the Interna-
tional Conference on Harmonisation and Good
Clinical Practice. Ethics committee approval was
obtained and all subjects were required to give
written, informed consent before taking part.
Study Design
Both studies were phase I, randomized, open-
label, two-way crossover studies of similar design
(figure 1) and were conducted at a single center in
France between December 2006 and May 2007
(Study A), or October 2003 and April 2004
(Study B).
In each study, subjects received two treatment
regimens in random order. In Study A, subjects
first received either (i) oral rifampicin 600mg/day
on days 1–31 with a single oral dose of vandeta-
nib 300mg on day 10; or (ii) a single oral dose
of vandetanib 300mg on day 1 (no rifampicin).
After a washout period of at least 6 weeks fol-
lowing the vandetanib dose, the subjects received
the alternative treatment. In Study B, subjects first
received either (i) oral itraconazole 200mg/day
on days 1–24 with a single oral dose of vandeta-
nib 300mg on day 4; or (ii) a single oral dose of
vandetanib 300mg on day 1 (no itraconazole).
After a 3-month washout period following the
dose of vandetanib, subjects received the alter-
native treatment.
Concomitant medication was not allowed in
either study, except for paracetamol (not to ex-
ceed 4 g in 24 hours) or where the investigator had
given prior consent.
Subjects in Study B were required to fast for
8 hours before any dose of vandetanib or itraco-
nazole, until 1 hour after dosing with itracona-
zole, or 2 hours after dosing with vandetanib with
or without itraconazole.
Pharmacokinetic Assessments
Blood samples for determination of vandeta-
nib concentrations in plasma were collected in
tubes containing lithium heparin anticoagulant
as follows: pre-dose and at 1, 2, 3, 4, 5, 6, 7, 8, 10,
12, 18, 24, 36, and 48 hours post-dose. In Study
A, samples were then collected at 24-hour inter-
vals up to 10 days post-dose, at 48-hour intervals
up to 18 days post-dose, and at 21 and 28 days
after the dose. In Study B, samples were collected
at 24-hour intervals up to 14 days post-dose, at
48-hour intervals up to 22 days post-dose, and at
25, 32, and 37 days after the dose.
In Study A, during the rifampicin treatment
period, blood samples for the determination of
rifampicin in plasma were collected at 2 hours
after the dose of rifampicin on days 1, 5, 10, 20,
and 31. In Study B, during the itraconazole treat-
ment period, blood samples for the determination
of itraconazole and hydroxy-itraconazole in plasma
were collected before dosing with vandetanib and
at 1, 2, 4, 6, 8, 12, 24, and 48 hours post-dose, at
48-hour intervals up to 22 days post-dose, and at
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25 and 37 days after the dose. These samples were
taken to confirm exposure to the CYP3A4 in-
ducer or inhibitor.
All blood samples were centrifuged within
30 minutes of collection and the plasma stored at
-20C. In Study A, plasma samples were analyzed
for vandetanib and its metabolites by Eurofins
Medinet, the Netherlands, and for rifampicin by
Pharma Bio-Research Group, the Netherlands.
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Fig. 1. Study design for (a) Study A and (b) Study B. PK = pharmacokinetic.
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vandetanib and itraconazole by BAS Analytics,
UK, and for hydroxy-itraconazole by MDS
Pharma Services, UK. The method used for anal-
ysis of vandetanib and its metabolites was protein
precipitation extraction followed by reversed
phase high-performance liquid chromatography
(RP-HPLC) and tandem mass spectrometry
(MS/MS). ‘Solvent first’ methodology, using
Isolute PPT+ protein precipitation plates (Biotage,
Sweden), was used to remove proteins from the
plasma sample. A total of 0.3mL acetonitrile,
internal standard, and 0.1mL sample were ap-
plied sequentially onto the PPT+ plates. After
homogenization, filtration was performed under
a vacuum and the filtrate was transferred to a
clean tube. After evaporation to dryness at 40C
under a stream of nitrogen, the dry residue was
reconstituted in 100 mL of mobile phase (aceto-
nitrile :water-ammonium acetate 8 : 2). Aliquots
of 10 mL were injected onto an HPLC system
comprising an Inertsil ODS-3 150 · 4.6mm C18
column (GL Sciences Inc., USA), a 4· 2mm C18
guard column, and a flow rate of 1.0mL/min.
Detection was performed using a PE Sciex tri-
ple quadrupole mass spectrometer with heated
nebulizer source. Vandetanib and vandetanib
N-oxide were detected by positive ion multiple
reaction monitoring (MRM) with mass settings
of 475-112 and 491-128. The mass settings for
the internal standard, 13C-D3-vandetanib, were
479-116.N-desmethylvandetanibwas detected by
MRM with mass settings of 461-98 and a mass
setting for the internal standard (AZ10031527) of
418-98. The peak areas of vandetanib and its
metabolites relative to the internal standard were
calculated and the concentration was determined
by reference to the relevant calibration curve. The
lower limits of quantificationwere 5ng/mL for van-
detanib, and 1ng/mL for N-desmethylvandetanib
and vandetanibN-oxide. For vandetanib, mean ac-
curacy was 105-110% and precision was 6.6-7.4%.
For N-desmethylvandetanib, mean accuracy was
99.5-104% and precision was 6.3-12.3%. For van-
detanib, mean accuracy was 100-105% and pre-
cision was 9.8-11.1%.
Pharmacokinetic parameters for vandetanib,
N-desmethylvandetanib, and vandetanib N-oxide
were determined from plasma concentration data
using non-compartmental methods (WinNonlin
Enterprise Version 4.1, Study A).
The primary pharmacokinetic parameters
were the area under the plasma concentration-time
curve (AUC) from time 0 to 504 hours post-dose
(AUC504) and the maximum plasma concentra-
tion (Cmax) of vandetanib.
Secondary pharmacokinetic parameters were
as follows: (i) for vandetanib (both studies) –
AUC from time zero to infinity (AUC¥), time to
reach Cmax (tmax), and elimination half-life (t½);
(ii) for metabolites (Study A only) – AUC504,
Cmax, AUC¥, tmax, t½, and the ratio of meta-
bolite exposure to vandetanib exposure (AUC504
ratio).
Pharmacokinetic parameters were calculated
as follows: Cmax and tmax were derived directly
from the AUC data; AUC504 was calculated by
the linear trapezoidal rule; the disposition rate
constant (lz) was calculated by log-linear re-
gression of the terminal portion of the AUC
where there were sufficient data to define this for
at least three half-lives and/or no more than 15%
of the total AUC was extrapolated; t½ was cal-
culated as 0.693/lz; the AUC up to the time of the
last quantifiable plasma concentration (AUClast)
was calculated by the linear trapezoidal rule and
extrapolated to infinity to using lz to obtain
AUC¥; and the ratio of metabolite exposure to
vandetanib exposure was determined from the
respective AUC504 values.
Safety and Tolerability Assessments
Safety and tolerability assessments included
adverse events, ECGs, vital signs, blood chem-
istry, hematology, and urinalysis.
Statistical Analyses
The safety analysis included all subjects who
had received at least one dose of any study med-
ication. Subjects with valid pharmacokinetic data
were included in the pharmacokinetic analysis.
For Study A only, plasma concentration data
were not available for a number of samples due to
analytical failure. Pharmacokinetic parameters
were only derived for subjects with adequate
plasma concentration data.
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The statistical analysis compared the primary
pharmacokinetic parameters (AUC504 and Cmax
of vandetanib) in the presence and absence of ri-
fampicin or itraconazole. AUC504 and Cmax were
logarithmically transformed and analyzed using a
mixed effects model with fixed effects for period
and treatment, with subject fitted as a random
effect (Study A) or an ANOVA model with fac-
tors fitted for the effect of sequence, subject with-
in sequence, period, and treatment (Study B).
Results were presented as adjusted geometric means
(geometric least square means [GLSmeans]) for
AUC504 and Cmax of vandetanib in the presence
and absence of rifampicin or itraconazole, and
the ratio of these GLSmeans with the corre-
sponding 90% confidence interval (CI). Coad-
ministration with rifampicin or itraconazole
would be considered to have no significant effect
on the pharmacokinetics of vandetanib if the
90% CI for the ratio of exposure lay between 0.8
and 1.25.
Sample sizes were based on estimates of within-
subject standard deviations (SDW) of pharma-
cokinetic parameters in previous studies.[14] A
sample size of 12 evaluable subjects for Study A
would provide 89% and 99% power of showing
that the 90% CI for the ratio of vandetanib in the
presence and absence of rifampicin lay between
0.8 and 1.25 for Cmax (SDW = 0.117) and AUC504
(SDW= 0.158), respectively. Ten evaluable sub-
jects in Study B would give 90% power of show-
ing that the 90% CI for the ratio of vandetanib in
the presence and absence of itraconazole lay be-
tween 0.8 and 1.25 for Cmax (SDW = 0.077 inflated
to 0.120, the upper 80% confidence limit, to ad-
just for small subject numbers). Since Cmax is
generally more variable than AUC, the study
was also expected to have adequate power for
AUC504. Each study aimed to recruit 16 subjects
to allow for potential withdrawals.
Results
Subjects
In Study A, 18 healthy male subjects received
study medication. The majority of subjects were
Caucasian (77.8%), mean age was 31.7 years
(range 21–44 years), and mean body mass index
(BMI) was 24.0 kg/m2 (range 19.4–29.1 kg/m2).
Three subjects withdrew from the study during
the first treatment period. Two of these subjects
withdrew after the first dose of rifampicin (one
due to an adverse event, one withdrew consent);
these subjects did not provide any pharmaco-
kinetic data. The third subject withdrew after re-
ceiving rifampicin for 19 days and a single dose of
vandetanib on day 10 because of adverse events;
data from this subject were included in the pharma-
cokinetic analysis. Thus, 18 and 16 subjects were
included in the safety and pharmacokinetic anal-
yses, respectively.
Sixteen healthy male subjects were enrolled in
Study B. Most subjects were Caucasian (68.8%),
mean age was 30.2 years (range 20–44 years), and
mean BMIwas 23.7 kg/m2 (range 19.0–29.0kg/m2).
Two subjects withdrew consent to participate in
the study during the first treatment period. One
of these subjects had received itraconazole for
11 days and a single dose of vandetanib on day 4;
the other had received a single dose of vandetanib
alone. All 16 subjects were included in the safety
and pharmacokinetic analyses.
In Study A, five subjects took anilides (such as
paracetamol) mostly for headache, one subject
took benzodiazepine derivatives for stress, and one
subject took phenothiazine derivatives for varicella
zoster virus infection (chickenpox). In Study B, one
subject took ibuprofen and metronidazole for a
dental abscess, and one subject used Locabiotal
spray (fusafungine) for rhinopharyngitis.
Pharmacokinetics
Study A (Cytochrome P450 [CYP] 3A4 Induction)
Rifampicin
Plasma concentrations of rifampicin measured
2 hours after dosing were mostly within the range
expected. Geometric mean [gmean] (coefficient of
variation [CV%]) plasma concentrations of ri-
fampicin on days 1, 5, 10, 20, and 31 were 12.2
(14.8), 10.7 (26.5), 6.5 (95.5), 8.9 (31.3), and 9.9
(22.3) mg/mL, respectively. One subject had a low
value (0.70 mg/mL) on day 10 compared with
concentrations in other subjects on day 10, and
with other concentrations in the same subject on
days 1, 5, 20, and 31.
42 Martin et al.
ª 2011 Martin et al., publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (1)
Vandetanib
Vandetanib was not detected in any pre-dose
plasma samples. Following a single oral dose of
vandetanib 300mg to healthy subjects, plasma
concentrations of vandetanib reached maximum
at a median time of 6 hours post-dose, and then
declined slowly with an approximate biphasic
disposition (figure 2). Plasma concentrations of
vandetanib were still quantifiable in most sub-
jects at 672 hours after dosing.
In the presence of rifampicin, plasma concen-
trations of vandetanib declined at a more rapid
rate, with divergence of the AUC at 48 hours
after dosing. The vandetanib gmean t½ was re-
duced from 217.6 hours to 116.3 hours. More
than half of the subjects had undetectable levels
of vandetanib by 504 hours after dosing.
There was a statistically significant reduc-
tion of 40% in the AUC504 of vandetanib when
a single dose of vandetanib 300mg was given
in combination with rifampicin compared with
vandetanib alone (GLSmean ratio 0.60; 90% CI
0.58, 0.63; table I). However, there was no
statistically significant difference in the Cmax of
vandetanib in the presence or absence of rifam-
picin (GLSmean ratio 1.03; 90% CI 0.95, 1.11;
table I).
Coadministration with rifampicin did not af-
fect the tmax of vandetanib (table II).
N-Desmethylvandetanib
Following a single dose of vandetanib 300mg,
plasma concentrations of N-desmethylvande-
tanib reached maximum at a median time of
5 hours post-dose, then declined slowly and were
still measurable in most subjects at 504 hours
(table II; figure 3). AUC¥ and t½ were not cal-
culable for 12 subjects because the terminal phase
was poorly defined or more than 20% of the
AUC was extrapolated. The ratio of exposure to
N-desmethylvandetanib relative to vandetanib
was low, indicating that plasma concentrations
of this metabolite were low compared with
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Fig. 2. Geometric mean (– SD) plasma concentrations of vandetanib following a single oral 300mg dose alone or in combination with
rifampicin. Insert shows more detailed plasma concentrations of vandetanib over the first 24 h. 1 = lower limit SD is not quantifiable <5ng/mL.
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N-desmethylvandetanib was »7% of the AUC504
of vandetanib.
In the presence of rifampicin, plasma concen-
trations of N-desmethylvandetanib were higher
than those observed following administration of
vandetanib alone (table II; figure 3). AUC504 and
Cmax of N-desmethylvandetanib increased by
266.0% and 414.3%, respectively, in the presence
of rifampicin compared with vandetanib alone;
tmax was unaltered by rifampicin. Exposure to
this metabolite, relative to the parent compound,
increased by 506.0% when vandetanib was dosed
in combination with rifampicin.
Vandetanib N-Oxide
Following a single oral dose of vandetanib
300mg to healthy subjects, maximum plasma con-
centrations of vandetanib N-oxide were attained
at a median time of 7 hours post-dose (table II;
figure 4). In the majority of subjects, plasma
concentrations of vandetanib N-oxide were non-
quantifiable by 96–240 hours post-dose. AUC¥
and t½ were not calculated as the terminal phases
were poorly defined. Since it was not possible to
calculate AUC504, exposure to metabolite rela-
tive to parent compound was assessed by compar-
ing AUClast using a common timepoint for both
vandetanib and vandetanib N-oxide (AUCct).
Exposure to vandetanib N-oxide was very low
compared with that of vandetanib. The AUCct of
vandetanib N-oxide was »2% of the AUCct of
vandetanib.
When vandetanib was coadministered with
rifampicin, there was a 179% increase in the Cmax
of vandetanib N-oxide (table II). Plasma con-
centrations of vandetanib N-oxide then declined
with an initial rapid phase, and were non-
quantifiable in all subjects by 36 hours post-dose.
AUClast for vandetanib N-oxide following coad-
ministration of vandetanib and rifampicin is not
directly comparable to the value derived follow-
ing dosing with vandetanib alone because these
parameters were not determined using a common
value of t. When AUCct was compared, a 126%
increase was observed following vandetanib and
rifampicin compared with vandetanib alone (gmean
44.26 vs 19.56 ngh/mL). Exposure to vandeta-
nib N-oxide relative to vandetanib was very sim-
ilar when vandetanib was given in combination
with rifampicin compared with vandetanib alone.
Study B (CYP3A4 Inhibition)
Itraconazole and Hydroxy-Itraconazole
Exposure to itraconazole and hydroxy-itraco-
nazole was similar to that seen in other studies
using the same dosing regimen.[15] On day 4, gmean
(CV%) AUC from time 0 to 24 hours (AUC24)
and Cmax of itraconazole were 5042 ngh/mL
(65.6) and 424.0 ng/mL (55.2), respectively. On
day 4, gmean (CV%) AUC24 and Cmax of
hydroxy-itraconazole were 7688 ngh/mL (56.8)
and 412.6 ng/mL (40.6), respectively.
Vandetanib
Vandetanib was not detected in any pre-dose
plasma samples. After a single dose of vandetanib
300mg in healthy subjects, absorption was mod-
erately slow with a median tmax of 5 hours both in
the absence and presence of itraconazole (figure 5).
Plasma concentrations of vandetanib declined in
a biexponential manner, irrespective of treatment.
Following vandetanib alone, plasma concentrations
Table I. Comparison of area under plasma concentration-time curve from time 0 to 504 hours (AUC504) and maximum plasma concentration
(Cmax) of vandetanib following a single oral dose of vandetanib 300mg alone or in combination with rifampicin
Parameter GLSmeana GLSmean ratiob (90% CI)c
vandetanib vandetanib + rifampicin
AUC504 (ngh/mL) 23 129 (n =12) 13 895 (n =12) 0.60 (0.58, 0.63)
Cmax (ng/mL) 178.2 (n =12) 183.1 (n = 13) 1.03 (0.95, 1.11)
a The number of subjects varies depending on availability of adequate plasma concentration data.
b Vandetanib in the presence of rifampicin : vandetanib in the absence of rifampicin.
c Coadministration with rifampicin is considered to have no statistically significant effect on the pharmacokinetics of vandetanib if the 90% CI
for the ratio of exposure lay between 0.8 and 1.25.
GLS = geometric least squares.
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were near to or below the level of quantification
in 12 of 15 subjects at 792 hours post-dose, while
following vandetanib in combination with itra-
conazole, low plasma concentrations of vande-
tanib were still detectable in 11 of 12 subjects at
this timepoint.
There was a statistically significant increase of
9% in the AUC504 (GLSmean ratio 1.09; 90% CI
1.01, 1.18) when a single dose of vandetanib
300mg was given in combination with itracona-
zole compared with vandetanib alone (table III).
The Cmax of vandetanib was not significantly in-
fluenced by itraconazole (GLSmean ratio 0.96;
90% CI 0.83, 1.11; table III).
There was no change in vandetanib tmax, and
only a small increase in vandetanib t½, when
vandetanib was coadministered with itraconazole
compared with vandetanib alone (table IV).
Safety and Tolerability
In Study A, 9 of 18 subjects (50.0%) experi-
enced at least one adverse event during the study.
Three (20.0%) and five (31.3%) subjects reported
adverse events following vandetanib in the ab-
sence and presence of rifampicin, respectively.
Three subjects (16.7%) reported adverse events while
receiving rifampicin alone. Headache was the
most frequently reported adverse event (table V).
One adverse event (mild abdominal pain) was
considered by the investigator to be causally re-
lated to vandetanib. One subject had two serious
adverse events (severe somnolence and drug tox-
icity requiring observation in hospital) while re-
ceiving rifampicin alone; this subject accidentally
took an overdose of bromazepam during a period
of stress due to examinations and was withdrawn
from the study. A second subject was withdrawn
from the study after 19 days due to varicella
zoster virus infection (chickenpox).
In Study B, 6 of 16 subjects (37.5%) reported
at least one adverse event during the study. Five
(31.3%) and one (6.3%) subjects reported adverse
events following vandetanib in the absence and
presence of itraconazole, respectively. Only one
adverse event (abdominal pain) was reported by
more than one subject (table V). One adverse
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by the investigator to be causally related to van-
detanib. There were no reports of serious adverse
events or discontinuations due to adverse events.
In Study A, there were no clinically important
changes in mean corrected QT (QTC) interval or
evidence of QTC interval prolongation associated
with vandetanib dosing, either alone or in com-
bination with rifampicin. One subject showed an
increase from baseline in QTC interval of >60ms
after receiving vandetanib in combination with
rifampicin. In Study B, mean QTC interval in-
creased after the dose of vandetanib by £20ms at
each timepoint. Three subjects had an increase
from baseline in QTC of >60ms; one of these
subjects also had episodes of sinus tachycardia.
Two additional subjects had intermittent epi-
sodes of marked sinus bradycardia, which were
considered to be a normal variation in healthy
males. None of these changes was considered to
be clinically important.
No clinically significant changes were observed
in vital signs, hematology, clinical chemistry, or
urinalysis, except for a trend towards small
treatment-related increases in systolic and dia-
stolic blood pressure, and mean arterial pressure
in Study B.
Discussion
Two phase I, randomized, open-label, two-
way crossover studies were carried out to inves-
tigate the potential for vandetanib to interact with
a potent CYP3A4 inducer (rifampicin) or a potent
CYP3A4 inhibitor (itraconazole). These studies
were considered necessary because CYP3A4 is
known to be involved in the metabolism of van-
detanib, and any pharmacokinetic interactions
with agents that induce or inhibit CYP3A4 may
have clinical implications. In both studies, two
single doses of vandetanib 300mg were given to
healthy subjects. Once daily dosing with vande-
tanib at 300mg was well tolerated by patients
with advanced solid tumors in previous phase I
studies.[16,17] Single doses of vandetanib were
used in the pharmacokinetic studies reported here
because it was not considered possible to conduct
multiple dose studies in healthy subjects due to
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Fig. 3. Geometric mean (– SD) plasma concentrations of N-desmethylvandetanib following a single oral dose of vandetanib 300mg alone or
in combination with rifampicin. Insert shows more detailed plasma concentrations of N-desmethylvandetanib over the first 24 h.
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dose pharmacokinetics can be accurately predicted
by single-dose pharmacokinetics for vandetanib.
AUC504 and Cmax were selected as primary phar-
macokinetic parameters for both studies. It was
important to measure the AUC over a long time
period because vandetanib is known to have a t½
of around 10 days but the maximum number of
doses of rifampicin and itraconazole that could
be given to healthy subjects also had to be con-
sidered. Therefore, rifampicin was given for 10 days
and itraconazole for 4 days before vandetanib was
dosed. This allowed the maximal induction and in-
hibition effects of the agents to be achieved before
vandetanib was administered. After vandetanib
administration, rifampicin and itraconazole were
continued for a further 20 days (approximately
two vandetanib half-lives) so that the induction
and inhibition effects were maintained over a
sustained period during which the vandetanib
pharmacokinetics were characterized. Plasma con-
centrations of vandetanib were below the level of
quantification in all samples that were collected
pre-dose, confirming that the washout periods
between treatment arms were of sufficient length.
Plasma concentrations of the metabolites of van-
detanib were not measured in the CYP3A4 in-
hibition study because our understanding of the
metabolism of vandetanib was incomplete when
this study was planned. By the time the CYP3A4
induction study was initiated, the two main meta-
bolites of vandetanib, N-desmethylvandetanib and
vandetanib N-oxide, had been identified and it was
considered important to investigate potential chan-
ges in the plasma levels of the metabolites to-
gether with the parent compound.
In both studies, vandetanib was absorbed
slowly, reaching Cmax at a median time of
5–6 hours after administration to healthy sub-
jects. Exposure to vandetanib following a single
300mg dose, assessed by AUC504 and Cmax, was
similar across the two studies. Plasma concen-
trations declined slowly with a biphasic dis-
position and a t½ of about 9 days (216 hours).
These results are consistent with those obtained
previously in healthy subjects.
In Study A, CYP3A4 was induced by admin-
istration of rifampicin 600mg/day for 10 days
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Fig. 4. Geometric mean (– SD) plasma concentrations of vandetanib N-oxide following a single oral dose of vandetanib 300mg alone or in
combination with rifampicin. Insert shows more detailed plasma concentrations of vandetanib N-oxide over the first 24 h. 1 = lower limit SD is
not quantifiable <5 ng/mL.
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has been shown to achieve maximal CYP3A4
induction within about 1 week[19] and has been
used in previous drug-drug interaction stud-
ies.[20,21] It was noted that one subject had a sig-
nificantly low plasma concentration of rifampicin
on the day that vandetanib was administered
compared with rifampicin concentrations mea-
sured before and in the days after vandetanib ad-
ministration. However, this subject had adequate
levels of rifampicin on all other occasions when it
was measured, and there was no evidence to sug-
gest that he had not taken the study medication.
Therefore, data from this subject were included
in the pharmacokinetic analysis. In all subjects,
rifampicin dosing was continued for a further
21 days after administration of vandetanib to
Table III. Comparison of area under plasma concentration-time curve from time 0 to 504 hours (AUC504) and maximum plasma concentration
(Cmax) of vandetanib following a single oral dose of vandetanib 300mg alone or in combination with itraconazole
Parameter GLSmean GLSmean ratioa (90% CI)b
vandetanib vandetanib + itraconazole
AUC504 (ngh/mL) 22 702 (n= 15)c 24 678 (n= 14)c,d 1.09 (1.01, 1.18)
Cmax (ng/mL) 195.6 (n =15)c 188.2 (n= 15)d 0.96 (0.83, 1.11)
a Vandetanib in the presence of itraconazole : vandetanib in the absence of itraconazole.
b Coadministration with itraconazole is considered to have no statistically significant effect on the pharmacokinetics of vandetanib if the 90%
CI for the ratio of exposure lay between 0.8 and 1.25.
c One subject was withdrawn during the first treatment period (vandetanib + itraconazole) and AUC504 was not calculable. This subject did not
receive vandetanib alone.
d One subject did not receive vandetanib + itraconazole.
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Fig. 5. Geometric mean (– SD) plasma concentrations of vandetanib following a single oral dose alone of vandetanib 300mg alone or in
combination with itraconazole. Insert shows more detailed plasma concentrations of vandetanib over the first 24 h.
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ensure that enzyme induction was maintained
throughout the pharmacokinetic sampling period.
Although the plasma half-life of rifampicin is
short (2–5 hours), and it is cleared from the body
within about 24 hours of dosing, rifampicin may
continue to exert an induction effect for up to
3weeks after the last dose.[22] A washout period of
at least 6 weeks was used in this study to ensure
that the effects of rifampicin had been dispersed
before crossover to the alternative treatment.
When vandetanib was administered in combi-
nation with rifampicin, vandetanib exposure, as
assessed by AUC504, was significantly reduced by
40%. The Cmax of vandetanib was unchanged by
rifampicin, and the AUC of vandetanib in the
presence and absence of rifampicin showed little
Table IV. Pharmacokinetic parameters of vandetanib following a single oral dose of vandetanib 300mg alone or in combination with
itraconazolea
Parameter Vandetanib Vandetanib + itraconazoleb,c
AUC504 (ngh/mL) 22 770 (20) [n = 15] 24 490 (21) [n = 14]
AUC¥ (ngh/mL) 27 870 (21) [n = 15] 31 690 (23) [n = 14]
Cmax (ng/mL) 191.3 (33.4) [n = 15] 189.1 (40.7) [n =15]
tmax (h) 5 (3–7)
d [n = 15] 5 (3–12)d [n = 15]
t½ (h) 209.2 (25.9) [n = 15] 235.5 (19.4) [n =14]
a Data are given as gmean (CV%), unless stated otherwise.
b One subject was withdrawn during the first treatment period (vandetanib + itraconazole) and AUC504, AUC¥, and t½ were not calculable.
This subject did not receive vandetanib alone.
c One subject did not receive vandetanib + itraconazole.
d Median (range).
AUC = area under plasma concentration-time curve; AUC¥ =AUC from time zero to infinity; AUC504 =AUC from time 0 to 504 hours;
Cmax =maximum plasma concentration; CV = coefficient of variation; gmean =geometric mean; t½ =elimination half-life; tmax= time to Cmax.
Table V. Adverse events reported following a single oral dose of vandetanib 300mg alone or in combination with rifampicin or itraconazole,
or during the rifampicin or itraconazole dosing period prior to the vandetanib dosea
Adverse event Vandetanib alone [n= 15] Vandetanib + rifampicin [n =16] Rifampicin alone [n =18]
Study A
Headache 1 (6.7) 3 (18.8) 2 (11.1)
Abdominal pain 1 (6.7) 2 (12.5) 0
Epistaxis 1 (6.7) 0 0
Rhinitis 1 (6.7) 0 0
Diarrhea 0 1 (6.3) 0
Face injury 0 1 (6.3) 0
Nausea 0 1 (6.3) 0
Neck pain 0 1 (6.3) 0
Varicella 0 1 (6.3) 0
Drug toxicity 0 0 1 (5.6)
Somnolence 0 0 1 (5.6)
Stress 0 0 1 (5.6)
Study B Vandetanib alone [n= 15] Vandetanib + itraconazole [n =15] Itraconazole alone [n = 15]
Abdominal pain 2 (13.3) 0 0
Nasopharyngitis 1 (6.7) 1 (6.7) 0
Bronchitis 1 (6.7) 0 0
Tooth abscess 1 (6.7) 0 0
a Data are given as n (%).
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difference for the first 24–48 hours post-dose.
These observations indicate that the bioavail-
ability of vandetanib was unaltered by CYP3A4
induction. Thus, the reduced AUC504 appeared
to be due to increased metabolic clearance of
vandetanib. Consequently, the vandetanib t½ was
reduced during administration of vandetanib in
combination with rifampicin.
The AUC504 of N-desmethylvandetanib was
increased by 266.0% in the presence of rifampi-
cin, consistent with CYP3A4 induction. AUC¥
of N-desmethylvandetanib was not calculated
for the majority of subjects as the accuracy of
the estimate was limited by the amount of ex-
trapolation that was required. Exposure to the
metabolite relative to the parent drug, as assessed
using AUC504 levels, increased from approx-
imately 7% to 43% during coadministration of
vandetanib with rifampicin, indicating that me-
tabolism by this route was increased. Plasma
concentrations of vandetanib N-oxide were very
low, and comparison of exposure to this metab-
olite compared with that of the parent drug by
measurement of AUC was not possible. Based on
Cmax, it appeared that exposure to vandetanib
N-oxide was increased by around 179% following
vandetanib dosing in combination with rifampi-
cin compared with vandetanib alone. However, it
should be noted that the change in absolute
plasma levels of vandetanib N-oxide was small,
and did not result in an obvious change in ex-
posure relative to the parent drug (1.8% vs 2.0%).
Overall, the results of this study are consistent
with in vitro data, which indicate that vandetanib
is a CYP3A4 substrate.[11] It is anticipated that
coadministration of vandetanib with a potent
CYP3A4 inducer could result in reduced steady-
state exposure to vandetanib. Although reduced
exposure to vandetanib has the potential to reduce
its efficacy, a clear relationship between exposure
and clinical effect has not been defined for vande-
tanib. Since N-desmethylvandetanib is of similar
potency to vandetanib, increased exposure to the
metabolite may compensate to some extent for re-
duced exposure to the parent compound.
In Study B, CYP3A4 was inhibited by admin-
istration of itraconazole 200mg/day for 4 days
before dosing with vandetanib. This itraconazole
regimen is commonly used in drug-drug inter-
action studies.[15,23,24] Based on the t½ of itraco-
nazole (»36 hours at steady state), it has been
predicted that its CYP3A4 inhibitory effect con-
tinues for about 2 weeks after the last dose.[25]
Thus, the extended washout period used in this
study (3 months) was considered adequate to
dissipate the action of itraconazole. Coadmin-
istration with itraconazole resulted in a small,
statistically significant increase (9%) in exposure
to vandetanib as assessed by AUC504, probably
due to reduced metabolic clearance consistent
with CYP3A4 inhibition. There was no evidence
of an effect on Cmax or tmax. The vandetanib t½
increased slightly when vandetanib was admin-
istered in combination with itraconazole. These
minor pharmacokinetic changes are not consid-
ered to be clinically relevant. The results of this
study indicate that coadministration of vandeta-
nib with a potent CYP3A4 inhibitor is unlikely to
have a clinically relevant effect on steady-state
exposure to vandetanib and would not require
contraindication or dosage adjustment.
In these studies, single doses of vandetanib
300mg were well tolerated by healthy subjects,
both alone and in combination with rifampicin or
itraconazole. The tolerability profile of vandeta-
nib was consistent with that observed in previous
single-dose studies in healthy subjects.
Conclusions
Exposure to vandetanib, as assessed by AUC504
in healthy subjects, was reduced by 40% when a
single dose was given in combination with the po-
tent CYP3A4 inducer rifampicin. Because of this, it
may be appropriate to avoid coadministration of
potent CYP3A4 inducers with vandetanib. Vande-
tanib exposure was increased by about 9% when
it was taken in combination with the CYP3A4
inhibitor itraconazole. It is unlikely that coad-
ministration of vandetanib and potent CYP3A4
inhibitors will need to be contraindicated.
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